Huons BioPharma broke ground for a 70-billion-won ($54.8 million) biomanufacturing plant in Jecheon, North Chungcheon, Tuesday.
Huons BioPharma was granted permission to start Phase 2 clinical trials of its botulinum toxin candidate, the company said Tuesday.
Huons BioPharma signed a deal potentially worth 97.2 billion won ($83.4 million) with Berlin, Germany’s Haemato Pharm to supply its Hutox botulinum toxin for sale in the European market.
Korea JoongAng Daily Sitemap